by Researchers at the Paul Scherrer Institute recently deciphered the structure of the CC chemokine receptor 7 (CCR7), a signaling protein. © Bogdan Hoda | Dreamstime.com Cancer cells use CCR7 to guide themselves into the lymphatic system, spreading cancer throughout the body. The resulting secondary tumors, called metastases, are responsible for most cancer deaths. This new understanding of CCR7 is a break through that forms a foundation for developing drugs that could lead to treatments to reduce the spread of certain types of cancer, including colorectal cancer, the second most common malignant tumor worldwide. Based on this work, scientists at the Swiss pharmaceutical giant Roche found a number of compounds in their database that might block the CCR7 signaling
Topics:
Investec considers the following as important: 3) Swiss Markets and News, 3.) Investec, Featured, newsletter
This could be interesting, too:
Nachrichten Ticker - www.finanzen.ch writes Krypto-Ausblick 2025: Stehen Bitcoin, Ethereum & Co. vor einem Boom oder Einbruch?
Connor O'Keeffe writes The Establishment’s “Principles” Are Fake
Per Bylund writes Bitcoiners’ Guide to Austrian Economics
Ron Paul writes What Are We Doing in Syria?
Researchers at the Paul Scherrer Institute recently deciphered the structure of the CC chemokine receptor 7 (CCR7), a signaling protein.
© Bogdan Hoda | Dreamstime.com
Cancer cells use CCR7 to guide themselves into the lymphatic system, spreading cancer throughout the body. The resulting secondary tumors, called metastases, are responsible for most cancer deaths.
This new understanding of CCR7 is a break through that forms a foundation for developing drugs that could lead to treatments to reduce the spread of certain types of cancer, including colorectal cancer, the second most common malignant tumor worldwide.
Based on this work, scientists at the Swiss pharmaceutical giant Roche found a number of compounds in their database that might block the CCR7 signaling protein and be used to develop a new drug to reduce the spread of cancer.
The Paul Scherrer Institute is Switzerland’s largest research institute, with 2,100 staff and an annual budget of around CHF407 million, according to the Institute’s website.
More on this:
Discovery article published in Cell (in English)
Tags: Featured,newsletter